Unusual movement in Hong Kong stock market | Bei Bo Pharmaceutical-B (02142.HK) rose more than 5% in the closing session, with clinical data of Pluribab single antibody treatment set to be announced soon. HBM7020 was previously launched overseas by BD.

According to the Securities Times APP, Porton Pharmaceutical Group-B (02142.HK) rose by more than 5% in the final trading session, with an increase of 5.38% at the time of publication, reaching 10.96 Hong Kong dollars, with a turnover of 140 million Hong Kong dollars.